Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
3.82%
Market Closed
Updated:
May 3, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
1.8
Current
11.2
Median
3.8
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=1.8
Enterprise Value
/
2.8m
Revenue
1.6m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
3.2m GBP | 1.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
220.9B USD | 5.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
182.8B USD | 4.4 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD | 3.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 6.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.1B CHF | 5.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 14.7 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 7.6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 9 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
24.9B USD | 3.4 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 7.9 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
1.7
2-Years Forward
EV/S
N/A
3-Years Forward
EV/S
N/A
You don't have any saved screeners yet
